CoChat
Sign Up
Cited by 446Adrenal and Paraganglionic TumorsAdrenal Hormones and DisordersNeuroendocrine Tumor Research Advances

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Clinical and Biological Features in the Prognosis of Adrenocortical Cancer: Poor Outcome of Cortisol-Secreting Tumors in a Series of 202 Consecutive Patients

Abiven, Gwenaelle, Coste, Joel, Groussin, Lionel, Anract, Philippe, Tissier, Frédérique, Legmann, Paul, Dousset, Bertrand, Bertagna, Xavier, Bertherat, Jérôme·2006·The Journal of Clinical Endocrinology & Metabolism
DOI 10.1210/jc.2005-2730
Open this paper in CoChat — free account

Abstract

CONTEXT: Adrenocortical carcinomas (ACC) are rare tumors with a poor prognosis. Few reports concerning large and homogeneous series are available. OBJECTIVE: We aimed to determine the clinical characteristics and outcome of ACC and to identify prognostic factors. DESIGN AND SETTING: This study is a descriptive and multivariate analysis of a cohort from a single endocrinology center. PATIENTS: A total of 202 consecutive patients with ACC were studied. RESULTS: The sex ratio (female to male) was 2.7. Mean age at diagnosis was 44 +/- 16 yr (range, 11-88 yr). We found that 154 patients (76%) had hypersecreting tumors [mostly cortisol and androgens (47%), cortisol alone (27%), or androgens alone (6%)] and 43 patients (21%) had metastases at diagnosis. At initial staging or during follow-up, 85 patients (42%) had liver metastases, 79 patients (39%) had lung metastases, and 20 patients had bone metastases (10%). The survival rate was 37% at 5 yr. Multivariate analysis identified the following independent prognostic factors associated with shorter survival: older age at diagnosis [hazard ratio (HR), 1.03; P < 0.0001], initial MacFarlane extension stages 3 (HR, 4.42; P = 0.005) and 4 (HR, 7.93; P < 0.0001), and cortisol hypersecretion (HR, 3.90; P < 0.0001). Treatment with 1,1-dichlorodiphenildichloroethane (o,p'DDD) in the 3 months after surgery increased the survival rate of patients with cortisol-secreting tumors (HR, 0.40; P = 0.04). CONCLUSION: This study highlights the better prognosis of ACC diagnosed at a noninvasive local stage, the particularly poor prognosis of patients with cortisol-secreting tumors, and the beneficial effect of o,p'DDD therapy in this subgroup of patients.

Overview

Integrity signals

Registry

Crossref · 10.1210/jc.2005-2730

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 34 references

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Abiven, G., Coste, J., Groussin, L., Anract, P., Tissier, F., Legmann, P., Dousset, B., Bertagna, X., & Bertherat, J.
Affiliations
  • Hôpital Cochin (FR)
  • Centre National de la Recherche Scientifique (FR)
ORCID
Venue
The Journal of Clinical Endocrinology & Metabolism
Publisher
The Endocrine Society
Published
2006-07
Volume
91
Issue
7
Pages
2650-2655
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
DOI
10.1210/jc.2005-2730
OpenAlex
W2140991656
Cited by
435
References
34
Citations by year
2026: 12 · 2025: 12 · 2024: 14 · 2023: 23 · 2022: 20 · 2021: 30 · 2020: 25 · 2019: 23 · 2018: 33 · 2017: 17 · 2016: 23 · 2015: 32 · 2014: 31 · 2013: 21 · 2012: 18
FWCI
15.59
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
  • Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
Keywords
adrenocortical carcinoma, prognosis, prognostic factors, survival, liver metastasis, lung metastasis, age at diagnosis, mitotane, adjuvant chemotherapy, androgen-secreting tumor
MeSH terms
Adrenal Cortex Neoplasms, Adult, Analysis of Variance, Androgens, Bone Neoplasms, Female, Humans, Hydrocortisone, Liver Neoplasms, Lung Neoplasms, Male, Middle Aged, Mitotane, Neoplasm Staging, Prognosis, Survival Rate, Chemotherapy, Adjuvant, Antineoplastic Agents, Hormonal

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review